I think the idea of a new nic would have been a fresh start.
Why bother otherwise?
Quite obviously, if people can recognise you (and they have!) it might be time to reconsider your approach.
I'm looking for any content in your posts which show you understand where the company is at right now.
And where the future is for SAVR and TAVR.
- Forums
- ASX - By Stock
- AVR
- Ann: SAVR Clinical Trial
Ann: SAVR Clinical Trial, page-73
Featured News
Add AVR (ASX) to my watchlist
(20min delay)
|
|||||
Last
$9.50 |
Change
-0.410(4.14%) |
Mkt cap ! $202.9M |
Open | High | Low | Value | Volume |
$9.50 | $9.61 | $9.31 | $97.61K | 10.27K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 840 | $9.50 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$9.67 | 923 | 6 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 902 | 9.500 |
1 | 730 | 9.410 |
1 | 99 | 9.310 |
1 | 2000 | 9.300 |
2 | 1044 | 9.250 |
Price($) | Vol. | No. |
---|---|---|
9.670 | 923 | 6 |
9.680 | 161 | 1 |
9.690 | 180 | 1 |
9.700 | 180 | 1 |
9.910 | 13 | 1 |
Last trade - 13.01pm 13/11/2024 (20 minute delay) ? |
Featured News
AVR (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online